Clinical Trials Browser

Phase 3 × rociletinib × Thoracic × Clear all

NCT02322281 2019-08-14

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

Phase 3 Terminated

149 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Recurrence